Samalin Investment Counsel’s Idexx Laboratories IDXX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-431
Closed -$242K 344
2026
Q1
$242K Sell
431
-7
-2% -$4.49K 0.09% 263
2025
Q4
$296K Sell
438
-6
-1% -$4.09K 0.11% 235
2025
Q3
$283K Buy
444
+3
+0.7% +$1.82K 0.1% 258
2025
Q2
$237K Buy
+441
New +$211K 0.09% 279
2024
Q4
Sell
-566
Closed -$286K 314
2024
Q3
$286K Sell
566
-15
-3% -$7.29K 0.12% 229
2024
Q2
$283K Hold
581
0.13% 225
2024
Q1
$314K Hold
581
0.15% 207
2023
Q4
$322K Sell
581
-7
-1% -$3.29K 0.16% 202
2023
Q3
$257K Sell
588
-3
-0.5% -$1.5K 0.15% 194
2023
Q2
$297K Buy
591
+2
+0.3% +$958 0.16% 179
2023
Q1
$295K Hold
589
0.18% 166
2022
Q4
$240K Buy
+589
New +$229K 0.15% 186
2022
Q3
Sell
-696
Closed -$244K 238
2022
Q2
$244K Sell
696
-240
-26% -$97.9K 0.17% 178
2022
Q1
$512K Buy
936
+31
+3% +$16.3K 0.31% 94
2021
Q4
$596K Buy
905
+47
+5% +$29.5K 0.36% 79
2021
Q3
$533K Buy
858
+31
+4% +$20.8K 0.35% 89
2021
Q2
$523K Sell
827
-6
-0.7% -$3.31K 0.34% 96
2021
Q1
$407K Sell
833
-55
-6% -$27.6K 0.27% 119
2020
Q4
$444K Sell
888
-219
-20% -$98K 0.33% 95
2020
Q3
$435K Sell
1,107
-89
-7% -$32.9K 0.39% 79
2020
Q2
$394K Sell
1,196
-1,063
-47% -$308K 0.41% 70
2020
Q1
$547K Sell
2,259
-155
-6% -$40.5K 0.73% 37
2019
Q4
$630K Buy
+2,414
New +$636K 0.53% 44

Other funds holding IDXX

Samalin Investment Counsel's IDXX Position: Q2 2026 in Review

Samalin Investment Counsel sold out of Idexx Laboratories (IDXX) in Q2 2026, closing a stake of 431 shares — an estimated $242K sold.

Samalin Investment Counsel first reported a position in IDXX in Q4 2019 and held it in 23 quarters. The position peaked at $630K in Q4 2019. 485 funds tracked by Wall St. Rank hold IDXX as of Q2 2026.

  • Samalin Investment Counsel reported no remaining Idexx Laboratories position as of Q2 2026 after selling out during the quarter.
  • Samalin Investment Counsel sold 431 Idexx Laboratories shares in Q2 2026, an estimated $242K.
  • Samalin Investment Counsel first reported a position in Idexx Laboratories in Q4 2019 and held it in 23 quarters.
  • Samalin Investment Counsel's Idexx Laboratories position peaked at $630K in Q4 2019.
  • 485 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2026.

Based on Samalin Investment Counsel's 13F filing for Q2 2026, filed 27 Jul 2026.